Targeting of proangiogenic signalling pathways in chronic inflammation

Nature Reviews Rheumatology

Volumn 12, Issue 2, 2016, Pages 111-122

  Tas, Sander W ^a   Maracle, Chrissta X ^a   Balogh, Emese ^b   Szekanecz, Zoltán ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN; ANGIOPOIETIN RECEPTOR; CHEMOKINE; CYTOKINE; FOCAL ADHESION KINASE; FOCAL ADHESION KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR INHIBITOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SPHINGOSINE KINASE 1; STAT PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; CELL ADHESION MOLECULE; MATRIX METALLOPROTEINASE; SIGNAL PEPTIDE;

ANGIOGENESIS; CHRONIC INFLAMMATION; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; HYPOXIA; INTRACELLULAR SIGNALING; MOLECULAR PATHOLOGY; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT PLANNING; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASE; DRUG EFFECTS; IMMUNOLOGY; INFLAMMATION; SPONDYLARTHRITIS; SYNOVIUM; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; CELL ADHESION MOLECULES; CHEMOKINES; HUMANS; INFLAMMATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MATRIX METALLOPROTEINASES; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; SPONDYLARTHRITIS; SYNOVIAL MEMBRANE; TREATMENT OUTCOME;

EID: 84956811659     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2015.164     Document Type: Review

References (138)

1. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1, 27-31 (1995).
2. Szekanecz, Z., Besenyei, T., Szentpetery, A. & Koch, A. E. Angiogenesis and vasculogenesis in rheumatoid arthritis. Curr. Opin. Rheumatol. 22, 299-306 (2011).
3. Szekanecz, Z. & Koch, A. E. Mechanisms of disease: angiogenesis in inflammatory diseases. Nat. Clin. Pract. Rheumatol. 3, 635-643 (2007).
4. Madri, J. A. & Williams, S. K. Capillary endothelial cell cultures: phenotypic modulation by matrix components. J. Cell. Biol. 97, 153-165 (1983).
5. Elshabrawy, H. A. et al. The pathogenic role of angiogenesis in rheumatoid arthritis. Angiogenesis http://dx.doi.org/10.1007/s10456-015-9477-2.
6. Marrelli, A. et al. Angiogenesis in rheumatoid arthritis: a disease specific process or a common response to chronic inflammation? Autoimmun. Rev. 10, 595-598 (2011).
7. Stapor, P. C., Sweat, R. S., Dashti, D. C., Betancourt, A. M. & Murfee, W. L. Pericyte dynamics during angiogenesis: new insights from new identities. J. Vasc. Res. 51, 163-174 (2014).
8. Cotran, R. S. & Pober, J. S. Cytokine-endothelial interactions in inflammation, immunity, and vascular injury. J. Am. Soc. Nephrol. 1, 225-235 (1990).
9. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182-1186 (1971).
10. Eltzschig, H. K. & Carmeliet, P. Hypoxia and inflammation. N. Engl. J. Med. 364, 656-665 (2011).
11. Ng, C. T. et al. Synovial tissue hypoxia and inflammation in vivo. Ann. Rheum. Dis. 69, 1389-1395 (2010).
12. Taylor, P. C. & Sivakumar, B. Hypoxia and angiogenesis in rheumatoid arthritis. Curr. Opin. Rheumatol. 17, 293-298 (2005).
13. Veale, D. J. & Fearon, U. Inhibition of angiogenic pathways in rheumatoid arthritis: potential for therapeutic targeting. Best Pract. Res. Clin. Rheumatol. 20, 941-947 (2006).
14. Maracle, C. X. & Tas, S. W. Inhibitors of angiogenesis: ready for prime time? Best Pract. Res. Clin. Rheumatol. 28, 637-649 (2014).
15. Kanakaraj, P. et al. Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis. MAbs 4, 600-613 (2012).
16. Asahara, T. et al. Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis. Circ. Res. 83, 233-240 (1998).
17. Izquierdo, E. et al. Immature blood vessels in rheumatoid synovium are selectively depleted in response to anti-TNF therapy. PLoS ONE 4, e8131 (2009).
18. Rico, M. C., Rough, J. J., Del Carpio-Cano, F. E., Kunapuli, S. P. & DeLa Cadena, R. A. The axis of thrombospondin-1, transforming growth factor β and connective tissue growth factor: an emerging therapeutic target in rheumatoid arthritis. Curr. Vasc. Pharmacol. 8, 338-343 (2009).
19. Brooks, P. C., Clark, R. A. & Cheresh, D. A. Requirement of vascular integrin αVβ3 for angiogenesis. Science 264, 569-571 (1994).
20. Shahrara, S., Castro-Rueda, H. P., Haines, G. K. & Koch, A. E. Differential expression of the FAK family kinases in rheumatoid arthritis and osteoarthritis synovial tissues. Arthritis Res. Ther. 9, R112 (2007).
21. Wilder, R. L. Integrin αVβ3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases. Ann. Rheum. Dis. 61 (Suppl. 2), ii96-ii99 (2002).
22. Hiromatsu, Y. & Toda, S. Mast cells and angiogenesis. Microsc. Res. Tech 60, 64-69 (2003).
23. Rabquer, B. J. et al. Junctional adhesion molecule-C is a soluble mediator of angiogenesis. J. Immunol. 185, 1777-1785 (2010).
24. Yoon, S. O., Park, S. J., Yun, C. H. & Chung, A. S. Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J. Biochem. Mol. Biol. 36, 128-137 (2003).
25. Benelli, R., Lorusso, G., Albini, A. & Noonan, D. M. Cytokines and chemokines as regulators of angiogenesis in health and disease. Curr. Pharm. Des. 12, 3101-3115 (2006).
26. Yoshida, S. et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor α-dependent angiogenesis. Mol. Cell. Biol. 17, 4015-4023 (1997).
27. Leibovich, S. J. et al. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha. Nature 329, 630-632 (1987).
28. Li, Q. & Verma, I. M. NF-κB regulation in the immune system. Nat. Rev. Immunol. 2, 725-734 (2002).
29. Hangai, M. et al. Sequential induction of angiogenic growth factors by TNF-α in choroidal endothelial cells. J. Neuroimmunol. 171, 45-56 (2006).
30. Strieter, R. M. et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J. Biol. Chem. 270, 27348-27357 (1995).
31. Salcedo, R. et al. Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: in vivo neovascularization induced by stromal-derived factor-1α. Am. J. Pathol. 154, 1125-1135 (1999).
32. Petit, I., Jin, D. & Rafii, S. The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neoangiogenesis. Trends Immunol. 28, 299-307 (2007).
33. Isozaki, T. et al. Evidence that CXCL16 is a potent mediator of angiogenesis and is involved in endothelial progenitor cell chemotaxis: studies in mice with K/B x N serum-induced arthritis. Arthritis Rheum. 65, 1736-1746 (2013).
34. Owen, J. L. & Mohamadzadeh, M. Macrophages and chemokines as mediators of angiogenesis. Front. Physiol. 4, 159 (2013).
35. Deng, J. et al. IFNγ-responsiveness of endothelial cells leads to efficient angiostasis in tumours involving down-regulation of Dll4. J. Pathol. 233, 170-182 (2014).
36. + T cells. Cancer Res. 63, 4095-5100 (2003).
37. Szekanecz, Z., Pakozdi, A., Szentpetery, A., Besenyei, T. & Koch, A. E. Chemokines and angiogenesis in rheumatoid arthritis. Front. Biosci. (Elite Ed.) 1, 44-51 (2009).
38. Szekanecz, Z. & Koch, A. E. Macrophages and their products in rheumatoid arthritis. Curr. Opin. Rheumatol. 19, 289-295 (2007).
39. Szekanecz, Z., Vegvari, A., Szabo, Z. & Koch, A. E. Chemokines and chemokine receptors in arthritis. Front. Biosci. (Schol. Ed.) 2, 153-167 (2010).
40. Ghosh, S. & Hayden, M. S. Celebrating 25 years of NF-κB research. Immunol. Rev. 246, 5-13 (2012).
41. Senftleben, U. et al. Activation by IKKα of a second, evolutionary conserved, NF-κB signaling pathway. Science 293, 1495-1499 (2001).
42. Karin, M. Nuclear factor-κB in cancer development and progression. Nature 441, 431-436 (2006).
43. Noort, A. R. et al. NF-κB-inducing kinase is a key regulator of inflammation-induced and tumour-associated angiogenesis. J. Pathol. 234, 375-385 (2014).
44. Morrison, D. K. MAP kinase pathways. Cold Spring Harb. Perspect. Biol. 4 a011254 (2012).
45. McKay, M. M. & Morrison, D. K. Integrating signals from RTKs to ERK/MAPK. Oncogene 26, 3113-3121 (2007).
46. Asahara, H. et al. Direct evidence of high DNA binding activity of transcription factor AP-1 in rheumatoid arthritis synovium. Arthritis Rheum. 40, 912-918 (1997).
47. Amin, M. A. et al. Interleukin-18 induces angiogenic factors in rheumatoid arthritis synovial tissue fibroblasts via distinct signaling pathways. Arthritis Rheum. 56, 1787-1797 (2007).
48. De Cesaris, P. et al. Activation of Jun N-terminal kinase/stress-activated protein kinase pathway by tumor necrosis factor α leads to intercellular adhesion molecule-1 expression. J. Biol. Chem. 274, 28978-28982 (1999).
49. Scaldaferri, F. et al. The role of MAPK in governing lymphocyte adhesion to and migration across the microvasculature in inflammatory bowel disease. Eur. J. Immunol. 39, 290-300 (2009).
50. Schirbel, A. et al. Pro-angiogenic activity of TLRs and NLRs: a novel link between gut microbiota and intestinal angiogenesis. Gastroenterology 144, 613-623 e9 (2013).
51. Wernert, N. et al. The Ets 1 transcription factor is upregulated during inflammatory angiogenesis in rheumatoid arthritis. J. Mol. Med. 80, 258-266 (2002).
52. Forough, R. et al. Transcription factor Ets-1 regulates fibroblast growth factor-1-mediated angiogenesis in vivo: role of Ets-1 in the regulation of the PI3K/AKT/MMP-1 pathway. J. Vasc. Res. 43, 327-337 (2006).
53. Russell, L. & Garrett-Sinha, L. A. Transcription factor Ets-1 in cytokine and chemokine gene regulation. Cytokine 51, 217-226 (2010).
54. Stamatovic, S. M., Keep, R. F., Mostarica-Stojkovic, M. & Andjelkovic, A. V. CCL2 regulates angiogenesis via activation of Ets-1 transcription factor. J. Immunol. 177, 2651-2661 (2006).
55. Manning, B. D. & Cantley, L. C. AKT/PKB signaling: navigating downstream. Cell 129, 1261-1274 (2007).
56. Li, G. Q. et al. PI3 kinase/Akt/HIF-1α pathway is associated with hypoxia-induced epithelial-mesenchymal transition in fibroblast-like synoviocytes of rheumatoid arthritis. Mol. Cell. Biochem. 372, 221-231 (2012).
57. Kumar, P., Amin, M. A., Harlow, L. A., Polverini, P. J. & Koch, A. E. Src and phosphatidylinositol 3-kinase mediate soluble E-selectin-induced angiogenesis. Blood 101, 3960-3968 (2003).
58. Amin, M. A. et al. Interleukin 18 induces angiogenesis in vitro and in vivo via Src and JNK kinases. Ann. Rheum. Dis. 69, 2204-2212 (2010).
59. Zhang, H. G. et al. Regulation of tumor necrosis factor α-mediated apoptosis of rheumatoid arthritis synovial fibroblasts by the protein kinase Akt. Arthritis Rheum. 44, 1555-1567 (2001).
60. Yu, W. et al. NKX2-3 transcriptional regulation of endothelin-1 and VEGF signaling in human intestinal microvascular endothelial cells. PLoS ONE 6, e20454 (2011).
61. Liu, J. & Agarwal, S. Mechanical signals activate vascular endothelial growth factor receptor-2 to upregulate endothelial cell proliferation during inflammation. J. Immunol. 185, 1215-1221 (2010).
62. O'Shea, J. J. & Murray, P. J. Cytokine signaling modules in inflammatory responses. Immunity 28, 477-487 (2008).
63. Walker, J. G. et al. Changes in synovial tissue JAK-STAT expression in rheumatoid arthritis in response to successful DMARD treatment. Ann. Rheum. Dis. 65, 1558-1564 (2006).
64. Walker, J. G. et al. Expression of JAK3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique JAK3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis. Ann. Rheum. Dis. 65, 149-156 (2006).
65. van der Pouw Kraan, T. C. et al. Rheumatoid arthritis is a heterogeneous disease: evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues. Arthritis Rheum. 48, 2132-2145 (2003).
66. Sengupta, T. K., Chen, A., Zhong, Z., Darnell, J. E. Jr & Ivashkiv, L. B. Activation of monocyte effector genes and STAT family transcription factors by inflammatory synovial fluid is independent of interferon γ. J. Exp. Med. 181, 1015-1025 (1995).
67. Yokota, A. et al. Preferential and persistent activation of the STAT1 pathway in rheumatoid synovial fluid cells. J. Rheumatol. 28, 1952-1959 (2001).
68. Fang, K., Zhang, S., Glawe, J., Grisham, M. B. & Kevil, C. G. Temporal genome expression profile analysis during T-cell-mediated colitis: identification of novel targets and pathways. Inflamm. Bowel. Dis. 18, 1411-1423 (2012).
69. Valdembri, D., Serini, G., Vacca, A., Ribatti, D. & Bussolino, F. In vivo activation of JAK2/STAT-3 pathway during angiogenesis induced by GM-CSF. FASEB J. 16, 225-227 (2002).
70. Infusino, G. A. & Jacobson, J. R. Endothelial FAK as a therapeutic target in disease. Microvasc. Res. 83, 89-96 (2012).
71. Sulzmaier, F. J., Jean, C. & Schlaepfer, D. D. FAK in cancer: mechanistic findings and clinical applications. Nat. Rev. Cancer 14, 598-610 (2014).
72. Tavora, B. et al. Endothelial FAK is required for tumour angiogenesis. EMBO Mol. Med. 2, 516-528 (2010).
73. Schlessinger, J. New roles for Src kinases in control of cell survival and angiogenesis. Cell 100, 293-296 (2000).
74. Hu, P. F., Chen, Y., Cai, P. F., Jiang, L. F. & Wu, L. D. Sphingosine-1-phosphate: a potential therapeutic target for rheumatoid arthritis. Mol. Biol. Rep. 38, 4225-4230 (2011).
75. Lai, W. Q. et al. Anti-inflammatory effects of sphingosine kinase modulation in inflammatory arthritis. J. Immunol. 181, 8010-8017 (2008).
76. Limaye, V. et al. Chronic increases in sphingosine kinase-1 activity induce a pro-inflammatory, proangiogenic phenotype in endothelial cells. Cell Mol. Biol. Lett. 14, 424-441 (2009).
77. Kitano, M. et al. Sphingosine 1-phosphate/sphingosine 1-phosphate receptor 1 signaling in rheumatoid synovium: regulation of synovial proliferation and inflammatory gene expression. Arthritis Rheum. 54, 742-753 (2006).
78. Sekiguchi, M. et al. Role of sphingosine 1-phosphate in the pathogenesis of Sjögren's syndrome. J. Immunol. 180, 1921-1928 (2008).
79. Nussbaum, C. et al. Sphingosine-1-phosphate receptor 3 promotes leukocyte rolling by mobilizing endothelial P-selectin. Nat. Commun. 6, 6416 (2015).
80. Masuko, K. et al. Sphingosine-1-phosphate modulates expression of vascular endothelial growth factor in human articular chondrocytes: a possible new role in arthritis. Int. J. Rheum. Dis. 15, 366-373 (2012).
81. Gao, W. et al. Notch signalling pathways mediate synovial angiogenesis in response to vascular endothelial growth factor and angiopoietin 2. Ann. Rheum. Dis. 72, 1080-1088 (2012).
82. Gao, W. et al. Notch-1 mediates hypoxia-induced angiogenesis in rheumatoid arthritis. Arthritis Rheum. 64, 2104-2113 (2012).
83. Dong, Y. et al. Oridonin inhibits tumor growth and metastasis through anti-angiogenesis by blocking the Notch signaling. PLoS ONE 9, e113830 (2014).
84. Iso, T., Hamamori, Y. & Kedes, L. Notch signaling in vascular development. Arterioscler. Thromb. Vasc. Biol. 23, 543-553 (2003).
85. Tamai, H. et al. Possible involvement of Notch signaling in the pathogenesis of Buerger's disease. Surg. Today 44, 307-313 (2013).
86. Furuya, K., Kaku, Y., Yoshida, K., Joh, K. & Kurosaka, D. Therapeutic effects of sunitinib, one of the anti-angiogenetic drugs, in a murine arthritis. Mod. Rheumatol. 24, 487-491 (2014).
87. Li, H. et al. Pazopanib, a receptor tyrosine kinase inhibitor, suppresses tumor growth through angiogenesis in dedifferentiated liposarcoma xenograft models. Transl. Oncol. 7, 665-671 (2014).
88. Xie, M., He, C. S., Huang, J. K. & Lin, Q. Z. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial. Eur. J. Cancer 51, 595-603 (2015).
89. Kendra, K. L. et al. A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors. Mol. Cancer Ther. 14, 461-469 (2014).
90. Bukowski, R. M., Yasothan, U. & Kirkpatrick, P. Pazopanib. Nat. Rev. Drug Discov. 9, 17-18 (2010).
91. Panek, R. L. et al. In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase. J. Pharmacol. Exp. Ther. 286, 569-577 (1998).
92. Kwak, J. H., Jung, J. K. & Lee, H. Nuclear factor-κB inhibitors; a patent review (2006-2010). Expert Opin. Ther. Pat. 21, 1897-1910 (2011).
93. Tas, S. W. et al. Local treatment with the selective IκB kinase β inhibitor NEMO-binding domain peptide ameliorates synovial inflammation. Arthritis Res. Ther. 8, R86 (2006).
94. Tas, S. W. et al. Amelioration of arthritis by intraarticular dominant negative IKK β gene therapy using adeno-associated virus type 5. Hum. Gene Ther. 17, 821-832 (2006).
95. Sehnert, B. et al. NF-κB inhibitor targeted to activated endothelium demonstrates a critical role of endothelial NF-κB in immune-mediated diseases. Proc. Natl Acad. Sci. USA 110, 16556-16561 (2013).
96. Choe, J. Y., Lee, S. J., Park, S. H. & Kim, S. K. Tacrolimus (FK506) inhibits interleukin-1β-induced angiopoietin-1, Tie-2 receptor, and vascular endothelial growth factor through down-regulation of JNK and p38 pathway in human rheumatoid fibroblast-like synoviocytes. Joint Bone Spine 79, 137-143 (2011).
97. Ohori, M., Takeuchi, M., Maruki, R., Nakajima, H. & Miyake, H. FR180204, a novel and selective inhibitor of extracellular signal-regulated kinase, ameliorates collagen-induced arthritis in mice. Naunyn Schmiedebergs Arch, Pharmacol, 374, 311-316 (2007).
98. Ennis, B. W. et al. Inhibition of tumor growth, angiogenesis, and tumor cell proliferation by a small molecule inhibitor of c-Jun N-terminal kinase. J. Pharmacol. Exp. Ther. 313, 325-332 (2005).
99. Han, Z. et al. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J. Clin. Invest. 108, 73-81 (2001).
100. Tate, C. M. et al. LY2228820 dimesylate, a selective inhibitor of p38 mitogen-activated protein kinase, reduces angiogenic endothelial cord formation in vitro and in vivo. J. Biol. Chem. 288, 6743-6753 (2013).
101. Hommes, D. et al. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 122, 7-14 (2002).
102. Hammaker, D. & Firestein, G. S. "Go upstream, young man": lessons learned from the p38 saga. Ann. Rheum. Dis. 69 (Suppl. 1), i77-i82 (2010).
103. Cohen, S. B. et al. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum. 60, 335-344 (2009).
104. Dotan, I. et al. A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease. Gut 59, 760-766 (2010).
105. Allen, L. F., Sebolt-Leopold, J. & Meyer, M. B. CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin. Oncol. 30, 105-116 (2003).
106. Henderson, Y. C., Chen, Y., Frederick, M. J., Lai, S. Y. & Clayman, G. L. MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo. Mol. Cancer Ther. 9, 1968-1976 (2010).
107. Matulonis, U. et al. Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma. Gynecol. Oncol. 136, 246-253 (2014).
108. Liu, P., Cheng, H., Roberts, T. M. & Zhao, J. J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 8, 627-644 (2009).
109. Oikawa, T. & Shimamura, M. Potent inhibition of angiogenesis by wortmannin, a fungal metabolite. Eur. J. Pharmacol. 318, 93-96 (1996).
110. Markman, B. et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Ann. Oncol. 23, 2399-2408 (2012).
111. Papadopoulos, K. P. et al. Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory lymphoma. Leuk. Lymphoma 56, 1763-1770 (2015).
112. Xing, X. et al. PP242 suppresses cell proliferation, metastasis, and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathway. Anticancer Drugs 25, 1129-1140 (2014).
113. van Vollenhoven, R. F. Small molecular compounds in development for rheumatoid arthritis. Curr. Opin. Rheumatol. 25, 391-397 (2013).
114. van Vollenhoven, R. F. et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N. Engl. J. Med. 367, 508-519 (2012).
115. Fleischmann, R. et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N. Engl. J. Med. 367, 495-507 (2012).
116. Burmester, G. R. et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 381, 451-460 (2013).
117. van der Heijde, D. et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 65, 559-570 (2013).
118. Keystone, E. C. et al. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann. Rheum. Dis. 74, 333-340 (2015).
119. Xin, H. et al. Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. Cancer Res. 71, 6601-6610 (2011).
120. Cabrita, M. A. et al. Focal adhesion kinase inhibitors are potent anti-angiogenic agents. Mol. Oncol. 5, 517-526 (2011).
121. Kurenova, E. et al. A FAK scaffold inhibitor disrupts FAK and VEGFR-3 signaling and blocks melanoma growth by targeting both tumor and endothelial cells. Cell Cycle 13, 2542-2553 (2014).
122. Golubovskaya, V. M. Targeting FAK in human cancer: from finding to first clinical trials. Front. Biosci. (Landmark Ed.) 19, 687-706 (2014).
123. Ozanne, J., Prescott, A. R. & Clark, K. The clinically approved drugs dasatinib and bosutinib induce antiinflammatory macrophages by inhibiting the salt-inducible kinases. Biochem. J. 465, 271-279 (2014).
124. Sidibe, A. et al. Soluble VE-cadherin in rheumatoid arthritis patients correlates with disease activity: evidence for tumor necrosis factor α-induced VE-cadherin cleavage. Arthritis Rheum. 64, 77-87 (2011).
125. Sun, C. et al. ADAM15 regulates endothelial permeability and neutrophil migration via Src/ERK1/2 signalling. Cardiovasc. Res. 87, 348-355 (2010).
126. Shin, K. O. et al. Ginsenoside compound K inhibits angiogenesis via regulation of sphingosine kinase-1 in human umbilical vein endothelial cells. Arch. Pharm. Res. 37, 1183-1192 (2014).
127. Gustin, D. J. et al. Structure guided design of a series of sphingosine kinase (SphK) inhibitors. Bioorg. Med. Chem. Lett. 23, 4608-4616 (2013).
128. Fouladi, M. et al. Phase I trial of MK-0752 in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study. J. Clin. Oncol. 29, 3529-3534 (2011).
129. Diaz-Padilla, I. et al. A phase II study of single-agent RO4929097, a γ-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: a study of the Princess Margaret, Chicago and California phase II consortia. Gynecol. Oncol. 137, 216-222 (2015).
130. Diaz-Padilla, I. et al. A phase Ib combination study of RO4929097, a γ-secretase inhibitor, and temsirolimus in patients with advanced solid tumors. Invest. New Drugs 31, 1182-1191 (2013).
131. Espinoza, I. & Miele, L. Notch inhibitors for cancer treatment. Pharmacol.Ther. 139, 95-110 (2013).
132. De Jesus-Acosta, A. et al. A phase II study of the γ secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma. Invest. New Drugs 32, 739-745 (2014).
133. Richter, S. et al. A phase I study of the oral γ secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575). Invest. New Drugs 32, 243-249 (2013).
134. Hayashi, I. et al. Neutralization of the γ-secretase activity by monoclonal antibody against extracellular domain of nicastrin. Oncogene 31, 787-798 (2011).
135. Noort, A. R., Tak, P. P. & Tas, S. W. Non-canonical NF-κB signaling in rheumatoid arthritis: Dr Jekyll and Mr Hyde? Arthritis Res. Ther. 17, 15 (2015).
136. Weinblatt, M. et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum. 54, 2807-2816 (2006).
137. 68Ga-PRGD2 PET/CT: a prospective proof-of-concept cohort study. Ann. Rheum. Dis. 73, 1269-1272 (2014).
138. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/(2015).